Charles D Meyers Selected Research

Symporters

1/2019

The effects of licogliflozin, a dual SGLT1/2 inhibitor, on body weight in obese patients with or without diabetes.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Charles D Meyers Research Topics

Disease

3	Hyperlipoproteinemia Type I (Lipoprotein Lipase Deficiency, Familial) 12/2017 - 10/2015
2	Body Weight (Weight, Body) 01/2019 - 01/2017
1	Type 2 Diabetes Mellitus (MODY) 01/2019
1	Diarrhea 01/2019
1	Flatulence 01/2019
1	Obesity 01/2019
1	Weight Loss (Weight Reduction) 01/2019
1	Abdominal Pain (Pain, Abdominal) 01/2019
1	Costello Syndrome 12/2017
1	Overweight 09/2015
1	Diabetes Mellitus 07/2006

Drug/Important Bio-Agent (IBA)

4	Diacylglycerol O-AcyltransferaseIBA 01/2017 - 09/2015
3	pradigastatIBA 11/2016 - 09/2015
2	Triglycerides (Triacylglycerol)IBA 12/2017 - 01/2017
1	Glucagon (Glukagon)FDA Link 01/2019
1	Glucose (Dextrose)FDA LinkGeneric 01/2019
1	Hormones (Hormone)IBA 01/2019
1	Insulin (Novolin)FDA Link 01/2019
1	licogliflozinIBA 01/2019
1	SodiumIBA 01/2019
1	SymportersIBA 01/2019
1	IncretinsIBA 01/2019
1	DiglyceridesIBA 12/2017
1	benzimidazoleIBA 01/2017
1	LipidsIBA 07/2006